Puma Biotechnology (NASDAQ:PBYI) Director Sells $83,592.00 in Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Allison Dorval sold 11,610 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $7.20, for a total value of $83,592.00. Following the transaction, the director directly owned 90,780 shares in the company, valued at $653,616. This trade represents a 11.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Puma Biotechnology Trading Up 0.8%

Shares of NASDAQ PBYI opened at $7.23 on Thursday. Puma Biotechnology, Inc. has a 12 month low of $3.03 and a 12 month high of $7.90. The stock has a 50 day moving average of $7.24 and a 200-day moving average of $6.60. The company has a market capitalization of $368.01 million, a P/E ratio of 15.06 and a beta of 1.21.

Puma Biotechnology (NASDAQ:PBYI) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.09. Puma Biotechnology had a return on equity of 20.30% and a net margin of 10.69%.The company had revenue of $44.81 million during the quarter, compared to the consensus estimate of $42.00 million. Analysts predict that Puma Biotechnology, Inc. will post 0.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on PBYI shares. Weiss Ratings downgraded Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Wall Street Zen downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, Puma Biotechnology has a consensus rating of “Hold”.

Institutional Trading of Puma Biotechnology

A number of institutional investors have recently modified their holdings of the stock. Barclays PLC lifted its position in shares of Puma Biotechnology by 1.9% during the 4th quarter. Barclays PLC now owns 81,434 shares of the biopharmaceutical company’s stock valued at $485,000 after acquiring an additional 1,553 shares during the period. Cerity Partners LLC lifted its position in shares of Puma Biotechnology by 18.2% during the 4th quarter. Cerity Partners LLC now owns 12,072 shares of the biopharmaceutical company’s stock valued at $72,000 after acquiring an additional 1,862 shares during the period. BNP Paribas Financial Markets lifted its position in shares of Puma Biotechnology by 39.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 2,290 shares during the period. Kathmere Capital Management LLC lifted its position in shares of Puma Biotechnology by 9.8% during the 1st quarter. Kathmere Capital Management LLC now owns 29,779 shares of the biopharmaceutical company’s stock valued at $190,000 after acquiring an additional 2,648 shares during the period. Finally, Baron Wealth Management LLC lifted its position in shares of Puma Biotechnology by 8.2% during the 1st quarter. Baron Wealth Management LLC now owns 38,278 shares of the biopharmaceutical company’s stock valued at $245,000 after acquiring an additional 2,886 shares during the period. 61.29% of the stock is currently owned by institutional investors.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.